A phase IIa, double-blind, placebo-controlled, randomised, parallel-design, four-week study to investigate the safety and efficacy of the oral renin inhibitor SPP635 once daily in patients with mild to moderate hypertension
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2011
At a glance
- Drugs SPP 635 (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 20 Jun 2008 Results presented at Hypertension 2008 according to a Speedel media release (9090328).
- 02 Nov 2006 New trial record.